Trends and changes in prescription opioid analgesic dispensing in Canada 2005-2012: An update with a focus on recent interventions

BMC Health Services Research

Volumn 14, Issue , 2014, Pages

  Fischer, Benedikt ^a,b,c   Jones, Wayne ^a   Rehm, Jürgen ^b,c,d  

^a SIMON FRASER UNIVERSITY   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Canada; Health policy; Oxycodone; Population health; Prescription opioids

Indexed keywords

NARCOTIC ANALGESIC AGENT; OXYCODONE;

CANADA; CLINICAL PRACTICE; EPIDEMIOLOGY; HUMAN; OPIOID-RELATED DISORDERS; PHARMACY; PRESCRIPTION; STATISTICS AND NUMERICAL DATA; TRENDS;

ANALGESICS, OPIOID; CANADA; DRUG PRESCRIPTIONS; HUMANS; OPIOID-RELATED DISORDERS; OXYCODONE; PHARMACIES; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84897670805     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-90     Document Type: Article

References (55)

1. International Narcotics Control Board (INCB), Narcotic Drugs Technical Report: Estimated World Requirements for 2013-Statistics for 2011 New York, NY: United Nations 2013
2. Pain management: a fundamental human right. Brennan F, Carr DB, Cousins M, Anesth Analg 2007 105 1 205 221 10.1213/01.ane.0000268145.52345.55 17578977
3. Access to pain treatment as a human right. Lohman D, Schleifer R, Amon JJ, BMC Med 2010 8 8 10.1186/1741-7015-8-8 20089155
4. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Fischer B, Argento E, Pain Physician 2012 15 3 Suppl S191 ES203 22786457
5. Prescription opioid misuse: Why so markedly higher in North America compared to the rest of the world? Fischer B, Keates A, Bühringer G, Reimer J, Rehm J, Addiction 2014 109 2 177 181 10.1111/add.12224 23692335
6. Variable use of opioid pharmacotherapy for chronic noncancer pain in Europe: causes and consequences. Galvez R, J Pain Palliat Care Pharmacother 2009 23 4 346 356 10.3109/15360280903323665 19947833
7. A first comparison between the consumption of and the need for opioid analgesics at country, regional, and global levels. Seya M, Gelders S, Achara OU, Milani B, Scholten WK, J Pain Palliat Care Pharmacother 2011 25 1 6 18 10.3109/15360288.2010.536307 21426212
8. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Van Zee A, Am J Public Health 2009 99 2 221 227 10.2105/AJPH.2007.131714 18799767
9. Prevalence and Key covariates of non-medical prescription opioid Use among the general secondary student and adult populations in Ontario, Canada. Fischer B, Ialomiteanu A, Boak A, Adlaf E, Rehm J, Mann R, Drug Alcohol Rev 2013 32 3 276 287 10.1111/dar.12025 23305232
10. Correlations between population levels of prescription opioid use and prescription opioid-related substance use treatment admissions in the USA and Canada since 2001. Fischer B, Nakamura N, Urbanoski K, Rush B, Rehm J, Public Health 2012 126 9 749 751 10.1016/j.puhe.2012.04.010 22770736
11. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN, CMAJ 2009 181 12 891 896 10.1503/cmaj.090784 19969578
12. Office of the Chief Coroner of Ontario, Office of the Chief Coroner Report for 2009-2011 Toronto, ON: Ministry of Community Safety and Correctional Services 2012
13. Drug and Alcohol Treatment Information System (DATIS), Substance Abuse Statistical Tables: Fiscal Year 2007/2008 to Fiscal Year 2011/2012 Toronto, ON: Centre for Addiction & Mental Health 2012
14. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005-2009. Fischer B, Jones W, Rehm J, Pharmacoepidemiol Drug Saf 2013 22 4 438 442 10.1002/pds.3404 23319301
15. The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits. Wisniewski AM, Purdy CH, Blondell RD, J Addict Dis 2008 27 1 1 11 10.1300/J069v27n01-01
16. Association between non-medical and prescriptive usage of opioids. Dasgupta N, Kramer ED, Zalman MA, Carino S, Smith MY, Haddox JD, Wright C, Drug Alcohol Depend 2006 82 2 135 142 10.1016/j.drugalcdep.2005.08.019 16236466
17. Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. Dhalla IA, Mamdani MM, Gomes T, Juurlink DN, Can Fam Physician 2011 57 3 92 e96 21402956
18. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Fischer B, Jones W, Krahn M, Rehm J, Pharmacoepidemiol Drug Saf 2011 20 12 1269 1277 10.1002/pds.2190 21755568
19. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. Madadi P, Hildebrandt D, Lauwers AE, Koren G, PLoS One 2013 8 4 60600 10.1371/journal. pone.0060600 23577131
20. Abuse A, Achieving a Balance: Tackling the Opioid Public Health Crisis Toronto: College of Physicians and Surgeons of Ontario 2010
21. Canadian Guidelines for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain Hamilton: National Opioid Use Guideline Group (NOUGG) 2010
22. Inquest jury seeks to take prescription opioids off Ontario's streets. Silversides A, BMJ 2011 343 4371 10.1136/bmj.d4371 21745797
23. Expert Working Group on Narcotic Addiction, The Way Forward: Stewardship for Prescription Narcotics in Ontario Ontario: Ontario Ministry of Health and Long-Term Care 2012
24. 'Opioid drought', Canadian-style? Potential implications of the 'natural experiment' of delisting oxycontin in Canada. Fischer B, Keates A, Int J Drug Policy 2012 23 6 495 497 10.1016/j.drugpo.2012.07.008 22940141
25. OxyContin delisting not the answer to opioid addiction, experts say. Weeks C, [ http://www.theglobeandmail.com/life/health-and-fitness/health/ conditions/oxycontin-delisting-not-the-answer-to-opioid-addiction-experts-say/ article548948/ ]
26. Time bomb. CBC: The Fifth Estate, [ http://www.cbc.ca/player/Shows/Shows/ the+fifth+estate/Season+37/ID/2237145419/ ]
27. Canada's deadly love affair with painkillers. Blackwell T, [ http://news.nationalpost.com/2011/11/14/canadas-deadly-love-affair-with- painkillers/ ]
28. Ontario slow to act on prescription drug reforms, doctors charge. Mehler-Paperny A, [ http://www.theglobeandmail.com/life/health-and-fitness/ ontario-slow-to-act-on-prescription-drug-reforms-doctors-charge/article547507/ ]
29. W5: Prescription for tragedy. CTV, [ http://www.ctvnews.ca/w5/w5- producer-stephanie-kampf-undercover-1.994042 ]
30. Representations of OxyContin in North American newspapers and medical journals. Whelan E, Asbridge M, Haydt S, Pain Res Manag 2011 16 4 252 258 22059195
31. IMSB Canadian compuscript audit. IMS Brogan (IMSB), [ http://www.imsbrogancapabilities.com/ ]
32. Canadian Compuscript Montreal: IMS Brogan 2013
33. ATC/DDD index. WHO Collaborating Centre for Drug Statistics Methodology, [ http://www.whocc.no/atc-ddd-index/ ]
34. Definition and general considerations. WHO Collaborating Centre for Drug Statistics Methodology, [ http://www.whocc.no/ddd/definition-and-general- considera/ ]
35. WHO's Pain ladder. World Health Organization (WHO), [ http://www.who.int/cancer/palliative/painladder/en/ ]
36. Population by year, by province and territory. Statistics Canada, [ http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo02a-eng.htm ]
37. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Cherny NI, Baselga J, de Conno F, Radbruch L, Ann Oncol 2010 21 3 615 626 10.1093/annonc/mdp581 20176694
38. Interprovincial variation in access to publicly funded pharmaceuticals: a review based on the WHO anatomical therapeutic chemical classification system. Potvin K, MacDonald K, Can Pharm J 2004 137 7 29 34 10.1177/171516350413700703
39. Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures. Demers V, Melo M, Jackevicius C, Cox J, Kalavrouziotis D, Rinfret S, Humphries KH, Johansen H, Tu JV, Pilote L, CMAJ 2008 178 4 405 409 10.1503/cmaj.070587 18268266
40. Morgan SG, Raymond CB, Mooney D, Martin D, The Canadian Rx Atlas: 2nd edition Vancouver, BC: University of British Columbia Centre for Health Services and Policy Research 2008
41. Efficacy of opioids for chronic pain: a review of the evidence. Ballantyne JC, Shin NS, Clin J Pain 2008 24 6 469 478 10.1097/AJP. 0b013e31816b2f26 18574357
42. Effectiveness of opioids in the treatment of chronic non-cancer pain. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L, Pain Physician 2008 11 2 Suppl 181 S200 18443639
43. The need for a Canadian pain strategy. Lynch ME, Pain Res Manag 2011 16 2 77 80 21499581
44. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D, Eur J Pain 2006 10 4 287 333 10.1016/j.ejpain.2005.06.009 16095934
45. Breaking the news or fueling the epidemic? Temporal association between news media report volume and opioid-related mortality. Dasgupta N, Mandl KD, Brownstein JS, PLoS One 2009 4 11 7758 10.1371/journal.pone.0007758 19924221
46. Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain. Fishman SM, Papazian JS, Gonzalez S, Riches PS, Gilson A, Pain Med 2004 5 3 309 324 10.1111/j.1526-4637. 2004.04049.x 15367312
47. Physicians charged with opioid analgesicprescribing offenses. Goldenbaum DM, Christopher M, Gallagher RM, Fishman S, Payne R, Joranson D, Edmondson D, McKee J, Thexton A, Pain Med 2008 9 6 737 747 10.1111/j.1526-4637.2008.00482.x 18657218
48. Usefulness of prescription monitoring programs for surveillance-analysis of schedule II opioid prescription data in Massachusetts, 1996-2006. Katz N, Panas L, Kim M, Audet AD, Bilansky A, Eadie J, Kreiner P, Paillard FC, Thomas C, Carrow G, Pharmacoepidemiol Drug Saf 2010 19 2 115 123 10.1002/pds.1878 20014166
49. Picard A, The Globe and Mail (Index-only) (Toronto): Globe & Mail The OxyContin switch: a lost battle in our war on pain. 2012.1
50. Commentary in response to Paulozzi et al.: prescription drug abuse and safe pain management. Fishman SM, Pharmacoepidemiol Drug Saf 2006 15 9 628 631 10.1002/pds.1292 16862601
51. Prescription drug monitoring programs and death rates from drug overdose. Paulozzi L, Kilbourne EM, Desai HA, Pain Med 2011 12 5 747 754 10.1111/j.1526-4637.2011.01062.x 21332934
52. Time series analysis of California's prescription monitoring program: impact on prescribing and multiple provider episodes. Gilson AM, Fishman SM, Wilsey BL, Casamalhuapa C, Baxi H, J Pain 2012 13 2 103 111 10.1016/j.jpain. 2011.09.006 22112420
53. Geographical variation in opioid prescribing and opioid-related mortality in Ontario. Gomes T, Juurlink DN, Moineddin R, Gozdyra P, Dhalla I, Paterson M, Mamdani MM, Healthc Q 2011 14 1 22 24 10.12927/hcq.2011.22153
54. Reductions in non-medical prescription opioid use among adults in Ontario, Canada: are recent policy interventions working? Fischer B, Ialomiteanu A, Kurdyak P, Mann RE, Rehm J, Subst Abuse Treat Prev Policy 2013 8 1 4 10.1186/1747-597X-8-4 23347822
55. National Advisory Committee on Prescription Drug Misuse, First Do No Harm: Responding to Canada's Prescription Drug Crisis Ottawa, ON: Canadian Centre on Substance Abuse 2013